BC
ACHN

Broadfin Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Broadfin Capital’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,000,000
Closed -$3.29M – 89
2014
Q1 		$3.29M Hold
1,000,000
– – 0.32% 68
2013
Q4 		$3.32M Buy
+1,000,000
New +$2.9M 0.44% 47

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Broadfin Capital's ACHN Position: Q2 2014 in Review

Broadfin Capital sold out of Achillion Pharmaceuticals (ACHN) in Q2 2014, closing a stake of 1,000,000 shares — an estimated $3.29M sold.

Broadfin Capital first reported a position in ACHN in Q4 2013 and held it in 2 quarters. The position peaked at $3.32M in Q4 2013. 115 funds tracked by Wall St. Rank hold ACHN as of Q2 2014.

  • Broadfin Capital reported no remaining Achillion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Broadfin Capital sold 1,000,000 Achillion Pharmaceuticals shares in Q2 2014, an estimated $3.29M.
  • Broadfin Capital first reported a position in Achillion Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Broadfin Capital's Achillion Pharmaceuticals position peaked at $3.32M in Q4 2013.
  • 115 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2014.

Based on Broadfin Capital's 13F filing for Q2 2014, filed 14 Aug 2014.